FOLH1 and prostate cancer: By using a bone metastatic model of prostate cancer, Hao and colleagues demonstrated that a PSMA-functionalized atelocollagen carrier of miRNA (miR-15-A and miR-16-1) prolonged the survival of mice significantly (p < 0.05) (mean survival: 57 days) compared to saline-treated (mean survival: 27.2 days), targeted control miR (mean survival: 28.2 days), or untargeted miR-15-A/16-1 (mean survival: 38 days) NP groups [86].